Andreas R Striebinger

USPTO Granted Patents = 18 (Patent Applications = 6)

CIPO Patents = 3 (Patent Applications = 7)

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 5.3

ph-index = 5

Forward Citations = 89(Granted Patents)

Company Filing History:

14 out of 150

Abb Vie Deutschland Gmbh & Co. Kg

Abbott Laboratories Corporation

patents

4. 1 out of 17

Abbvie Deutschland Gmbh and Co Kg

patents

where one patent can have more than one assignee

Years Active: 2011-2020

Loading Chart...

18 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10538581 - Anti-Aβ globulomer 4D10 antibodies (2020-01-21),

2. 10464976 - Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof (2019-11-05),

3. 10323084 - Monoclonal antibodies against amyloid beta protein and uses thereof (2019-06-18),

4. 10208109 - Monoclonal antibodies against amyloid beta protein and uses thereof (2019-02-19),

5. 10047121 - Amyloid-beta binding proteins (2018-08-14),

6. 9951125 - Aβ conformer selective anti-Aβ globulomer monoclonal antibodies (2018-04-24),

7. 9822171 - Amyloid-beta binding proteins (2017-11-21),

8. 9540432 - Anti-Aβ globulomer 7C6 antibodies (2017-01-10),

9. 9394360 - Aβ conformer selective anti-Aβ globulomer monoclonal antibodies (2016-07-19),

10. 9359430 - Abeta conformer selective anti-Abeta globulomer monoclonal antibodies (2016-06-07),

11. 9176150 - Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof (2015-11-03),

12. 9062101 - Amyloid-beta binding proteins (2015-06-23),

13. 8987419 - Amyloid-beta binding proteins (2015-03-24),

14. 8877190 - Aβ conformer selective anti-Aβ globulomer monoclonal antibodies (2014-11-04),

15. 8691224 - Anti-Aβ globulomer 5F7 antibodies (2014-04-08),

Title: Innovations and Contributions of Andreas R Striebinger

Introduction

Andreas R Striebinger is a notable inventor based in Speyer, Germany. He has made significant contributions to the field of biomedical research, particularly in the development of antibodies related to Alzheimer's disease and other amyloidoses. With a total of 18 patents to his name, Striebinger's work has the potential to impact therapeutic and diagnostic approaches in neurology.

Latest Patents

Striebinger's latest patents include the development of Anti-Aβ globulomer 4D10 antibodies. These antibodies exhibit a binding affinity to Aβ(20-42) globulomer that surpasses their affinity to Aβ(1-42) globulomer. The patents cover various aspects, including antigen-binding moieties, hybridomas, nucleic acids, vectors, and host cells involved in the production of these antibodies. Additionally, the patents detail methods for producing the antibodies, compositions that include them, and their therapeutic and diagnostic uses, particularly in relation to Alzheimer's disease. Another significant patent involves neuromodulatory oligomers of the amyloid-β(1-42) protein, focusing on a reproducible production method that yields high quantities of the oligomer. This invention also encompasses the generation of oligomer-specific antibodies and the discovery of substances that interact with these oligomers.

Career Highlights

Throughout his career, Striebinger has worked with prominent companies such as AbbVie Deutschland GmbH & Co. KG and AbbVie Inc. His work in these organizations has allowed him to advance his research and contribute to the development of innovative therapeutic solutions.

Collaborations

Striebinger has collaborated with notable colleagues, including Heinz Hillen and Stefan Barghorn. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his research.

Conclusion

Andreas R Striebinger's contributions to the field of biomedical research, particularly in the development of antibodies for Alzheimer's disease, highlight his innovative spirit and dedication to improving healthcare. His extensive patent portfolio reflects his commitment to advancing scientific knowledge and therapeutic options.

This text is generated by artificial intelligence and may not be accurate.